Top 10 Companies in the (S)-3-Amino-2,3,4,5-Tetrahydro-2-oxo-1H-1-benzazepine-1-acetatic acid-1,2-dimethylethyl ester (CAS 109010-60-8) Market (2026): Market Leaders Powering Global Pharmaceutical Supply Chains

MARKET INSIGHTS

Global (S)-3-Amino-2,3,4,5-Tetrahydro-2-oxo-1H-1-benzazepine-1-acetatic acid-1,2-dimethylethyl ester (CAS 109010-60-8) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(S)-3-Amino-2,3,4,5-Tetrahydro-2-oxo-1H-1-benzazepine-1-acetatic acid-1,2-dimethylethyl ester, identified by CAS number 109010-60-8, is a chiral pharmaceutical intermediate of significant importance in the synthesis of benazepril and related ACE inhibitor compounds. This benzazepine derivative serves as a key building block in cardiovascular drug development, particularly in the production of antihypertensive agents.

The market is witnessing steady growth driven by rising global demand for cardiovascular therapeutics, increasing prevalence of hypertension, and expanding pharmaceutical manufacturing activities across North America, Europe, and Asia-Pacific. Furthermore, the compound’s critical role as a synthetic intermediate in ACE inhibitor drug pipelines continues to sustain procurement demand among leading API manufacturers and contract research organizations worldwide.

(S)-3-Amino-2,3,4,5-Tetrahydro-2-oxo-1H-1-benzazepine-1-acetatic acid-1,2-dimethylethyl ester (CAS 109010-60-8) Market – View in Detailed Research Report

1️⃣ 1. Hetero Labs Limited

Headquarters: Chennai, India
Key Offering: High purity chiral intermediates for cardiovascular APIs

Hetero Labs Limited is a leading fine chemical manufacturer with extensive cGMP facilities, providing robust synthesis of (S)-3-Amino-2,3,4,5-Tetrahydro-2-oxo-1H-1-benzazepine intermediates for global pharmaceutical companies.

Sustainability Initiatives:

• Implementation of green chemistry protocols reducing hazardous waste
• Energy‑efficient production processes to lower carbon footprint
• Waste minimization through process optimization

• Strong GMP compliance across all manufacturing sites
• Advanced chiral resolution technologies ensuring >99% ee
• Strategic partnerships with major API manufacturers

2️⃣ 2. MSN Laboratories Private Limited

Headquarters: Chennai, India
Key Offering: Scalable chiral synthesis and resolution services

MSN Laboratories is renowned for its cost‑effective, high‑yield processes for (S)-configured benzazepine intermediates, catering to generic and innovator drug manufacturers worldwide.

Sustainability Initiatives:

• Use of renewable feedstocks in synthetic routes
• Implementation of closed‑loop water systems
• Continuous improvement of energy efficiency

• Robust quality management system with ICH Q7 compliance
• Extensive experience in multi‑step chiral synthesis
• Strong technical support for CDMOs

3️⃣ 3. Aurobindo Pharma Limited

Headquarters: Hyderabad, India
Key Offering: Integrated API production and chiral intermediates

Aurobindo Pharma combines upstream synthesis of chiral intermediates with downstream API manufacturing, enabling end‑to‑end solutions for cardiovascular drug development.

Sustainability Initiatives:

• Commitment to 30% renewable energy usage in manufacturing
• Zero‑waste manufacturing initiatives
• Corporate social responsibility in health education

• Large‑scale production capacity for benazepril intermediates
• Strong global supply chain management
• High regulatory compliance across major markets

4️⃣ 4. Daiichi Sankyo Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: Proprietary chiral synthesis platforms for cardiovascular APIs

Daiichi Sankyo leverages advanced catalytic processes to deliver high‑purity (S)-benzazepine intermediates, supporting its proprietary ACE inhibitor pipelines.

Sustainability Initiatives:

• Investment in green chemistry research
• Reduction of hazardous solvent usage
• Efficient resource utilization

• Extensive R&D portfolio in chiral chemistry
• Strong GMP and regulatory track record
• Global distribution network

5️⃣ 5. Zhejiang Huahai Pharmaceutical Co., Ltd.

Headquarters: Hangzhou, China
Key Offering: Custom chiral intermediate synthesis and scale‑up

Zhejiang Huahai specializes in tailored synthesis of (S)-benzazepine intermediates for both domestic and international pharmaceutical clients.

Sustainability Initiatives:

• Implementation of eco‑friendly catalytic systems
• Water recycling and waste reduction programs
• Adoption of digital process monitoring

• High flexibility in order fulfillment
• Strong quality control with >99% ee
• Collaborations with global CDMOs

6️⃣ 6. Dr. Reddy’s Laboratories Ltd.

Headquarters: Hyderabad, India
Key Offering: High‑purity chiral intermediates for generic APIs

Dr. Reddy’s offers reliable supply of (S)-benzazepine intermediates, supporting its extensive generic drug portfolio across cardiovascular therapeutics.

Sustainability Initiatives:

• Energy‑efficient manufacturing lines
• Waste minimization through process optimization
• Community health outreach programs

• Robust GMP and ICH Q7 compliance
• Strong supply chain resilience
• Global presence in over 100 countries

7️⃣ 7. Ipca Laboratories Limited

Headquarters: Chennai, India
Key Offering: Scalable chiral intermediate production

Ipca Laboratories provides cost‑effective, high‑yield synthesis of (S)-configured benzazepine intermediates for generic drug manufacturers.

Sustainability Initiatives:

• Implementation of green solvents in synthesis
• Water and energy conservation measures
• Continuous improvement of process safety

• Strong technical support for CDMOs
• High batch consistency and purity
• Expanding production capacity

8️⃣ 8. Glenmark Pharmaceuticals Ltd.

Headquarters: Mumbai, India
Key Offering: Chiral intermediate manufacturing for cardiovascular APIs

Glenmark offers high‑quality (S)-benzazepine intermediates with a focus on regulatory compliance and rapid delivery.

Sustainability Initiatives:

• Energy‑efficient production processes
• Waste minimization strategies
• Adoption of renewable energy sources

• Strong GMP compliance across facilities
• High purity and enantiomeric excess
• Global distribution network

9️⃣ 9. Laurus Labs Limited

Headquarters: Chennai, India
Key Offering: Custom chiral synthesis and resolution services

Laurus Labs delivers tailored (S)-benzazepine intermediates with a focus on rapid turnaround for CDMOs and API manufacturers.

Sustainability Initiatives:

• Green chemistry practices in synthesis
• Efficient resource utilization
• Continuous improvement of safety protocols

• Strong technical expertise in chiral chemistry
• High scalability for large orders
• Robust quality assurance systems

🔟 10. Lupin Limited

Headquarters: Ahmedabad, India
Key Offering: High‑volume chiral intermediate production

Lupin provides large‑scale manufacturing of (S)-benzazepine intermediates, supporting global generic drug production for cardiovascular therapeutics.

Sustainability Initiatives:

• Energy‑efficient manufacturing facilities
• Water conservation and recycling
• Commitment to reducing carbon footprint

• Strong GMP and regulatory compliance
• High purity and consistency
• Global supply chain reach

Download FREE Sample Report

Get Full Report Here

Outlook

The (S)-3-Amino-2,3,4,5-Tetrahydro-2-oxo-1H-1-benzazepine-1-acetatic acid-1,2-dimethylethyl ester market is poised for continued expansion as global cardiovascular drug development intensifies. Demand for high‑purity, enantiomerically pure intermediates will drive investment in advanced chiral synthesis technologies and green chemistry initiatives, ensuring sustainable growth across the supply chain.

Future Trends

• Expansion of generic cardiovascular drug markets in emerging economies
• Increasing collaboration between CDMOs and intermediate suppliers for long‑term supply agreements
• Adoption of biocatalytic and flow chemistry methods to enhance scalability and reduce environmental impact
• Growth of research and development applications beyond ACE inhibitors, exploring neurological and oncological uses of benzazepine scaffolds
• Enhanced regulatory focus on enantiomeric purity and quality assurance across all markets